Short answer
ImmunityBio, Inc. (IBRX) filed an 8-K current report with the SEC on April 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Preliminary unaudited results cover quarter ended March 31, 2026.
ImmunityBio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary unaudited results cover quarter ended March 31, 2026
- Figures remain subject to closing procedures and final adjustments
- Actual results may differ materially in the forthcoming Form 10-Q
- Company updates and detailed preliminary results available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Preliminary Q1 2026 net product revenue $44.2M, up 168% year over year and 15% sequentially from Q4 2025
- ANKTIVA unit sales volume increased 168% year over year, indicating expanding U.S. urologist adoption
- Cash, equivalents and marketable securities totaled $380.9M at March 31, 2026, supporting commercial expansion and clinical development
- ANKTIVA approved or authorized in five jurisdictions covering approximately 34 countries, expanding international commercialization potential
- QUILT-2.005 BCG-naïve CIS trial fully enrolled; supplemental BLA submission remains targeted for 2026, creating a potential regulatory catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ImmunityBio, Inc. 8-K filings
Get the next IBRX 8-K as it lands
Follow IBRX for push alerts, or ask the research agent what this filing means.